JP6242636B2 - Bacteriostatic agent against odor-causing bacteria - Google Patents
Bacteriostatic agent against odor-causing bacteria Download PDFInfo
- Publication number
- JP6242636B2 JP6242636B2 JP2013190027A JP2013190027A JP6242636B2 JP 6242636 B2 JP6242636 B2 JP 6242636B2 JP 2013190027 A JP2013190027 A JP 2013190027A JP 2013190027 A JP2013190027 A JP 2013190027A JP 6242636 B2 JP6242636 B2 JP 6242636B2
- Authority
- JP
- Japan
- Prior art keywords
- odor
- fatty acid
- propylene glycol
- bacteriostatic agent
- causing bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、腋臭原因菌に対する静菌剤に関し、詳しくは、皮膚刺激性が弱く、安全性の高い腋臭原因菌に対する静菌剤に関する。 The present invention relates to a bacteriostatic agent for odor-causing bacteria, and in particular, relates to a bacteriostatic agent for odor-causing bacteria with low skin irritation and high safety.
人に不快感を与える腋臭は、汗が皮脂と混ざり、それがコリネバクテリウム(Corynebacterium)属菌などの皮膚常在菌と称される微生物により分解され悪臭物質を産生することにより発生する。そこで、従来から、この腋臭を含む体臭の発生を抑制するために、体臭防止用薬剤として、塩化アルミニウム等の制汗剤、塩化ベンザルコニウム等の殺菌剤、酸化亜鉛等の消臭剤などが用いられている。しかし、従来の体臭防止用薬剤には、皮膚刺激性が強いなどの問題があった。 The odor that causes discomfort to humans is generated when sweat mixes with sebum, which is decomposed by microorganisms called skin resident bacteria such as Corynebacterium and produces malodorous substances. Therefore, conventionally, in order to suppress the generation of body odor including this bad odor, antiperspirants such as aluminum chloride, bactericides such as benzalkonium chloride, deodorizers such as zinc oxide, etc. are used as body odor prevention agents. It is used. However, conventional chemicals for preventing body odor have problems such as strong skin irritation.
腋臭原因菌に対する静菌剤及び皮膚外用品に関する従来技術としては、中鎖脂肪酸エステルを含有してなるわきが防止剤(特許文献1)、炭素数8〜22を有する脂肪酸のショ糖脂肪酸エステルを有効成分とするコリネバクテリウム属菌に対する抗菌剤(特許文献2)、クエン酸エステル及び炭素数8〜22を有する脂肪酸のショ糖エステルを有効成分とする腋臭の原因菌用抗菌剤(特許文献3)などが開示されているが、一長一短がありより好ましい腋臭原因菌に対する静菌剤が求められていた。 As conventional techniques related to bacteriostatic agents against bad odor-causing bacteria and skin external products, a side-arm inhibitor containing a medium-chain fatty acid ester (Patent Document 1), a sucrose fatty acid ester of a fatty acid having 8 to 22 carbon atoms is effective. Antibacterial agent against corynebacterium as a component (Patent Document 2), antibacterial agent for causal odor causing bacteria containing citrate ester and sucrose ester of fatty acid having 8 to 22 carbon atoms (Patent Document 3) However, there are advantages and disadvantages, and a more preferable bacteriostatic agent for the odor-causing bacteria has been demanded.
本発明は、皮膚刺激性が弱く、安全性の高い腋臭原因菌に対する静菌剤を提供することを目的とする。 An object of this invention is to provide the bacteriostatic agent with respect to a bad smell causative microbe with weak skin irritation.
本発明者は、上記課題を解決する為に鋭意研究を重ねた結果、一定条件のプロピレングリコール脂肪酸エステルが上記課題を解決することを見出した。そして、これらの知見に基づきさらに研究を重ね、本発明を完成するに至った。
すなわち、本発明は、
(1)構成する脂肪酸として炭素数が8〜14の脂肪酸を1種又は2種以上を含有し、モノエステル体の含有量が90質量%以上のプロピレングリコール脂肪酸エステルであることを特徴とする腋臭原因菌に対する静菌剤、
(2)上記(1)に記載の静菌剤を含有することを特徴とする腋臭用皮膚外用剤、
からなっている。
As a result of intensive studies in order to solve the above problems, the present inventor has found that propylene glycol fatty acid esters under certain conditions solve the above problems. Based on these findings, further studies have been made and the present invention has been completed.
That is, the present invention
(1) A malodor characterized by being a propylene glycol fatty acid ester containing one or more fatty acids having 8 to 14 carbon atoms as a constituent fatty acid and having a monoester content of 90% by mass or more Bacteriostatic agent against causative bacteria,
(2) A skin odor external preparation for malodor containing the bacteriostatic agent according to (1) above,
It is made up of.
本発明の腋臭原因菌に対する静菌剤は、皮膚刺激性が弱いため安全性が高く、且つ腋臭原因菌を有効に静菌するという効果を有する。 The bacteriostatic agent for the odor-causing bacteria of the present invention is highly safe because of its weak skin irritation, and has the effect of effectively bacterizing the odor-causing bacteria.
本発明の腋臭原因菌に対する静菌剤は、構成する脂肪酸として炭素数が8〜14の脂肪酸を1種又は2種以上を含有し、モノエステル体の含有量が90質量%以上のプロピレングリコール脂肪酸エステルである。 The bacteriostatic agent for odor-causing bacteria of the present invention contains one or more fatty acids having 8 to 14 carbon atoms as the constituent fatty acid, and a monoester content of 90% by mass or more. Ester.
上記プロピレングリコール脂肪酸エステルを構成する炭素数が8〜14の脂肪酸としては、飽和脂肪酸、不飽和脂肪酸のいずれでもよく、好ましくは、炭素数8〜14の直鎖の飽和脂肪酸(例えばカプリル酸、ぺラルゴン酸、カプリン酸、ラウリン酸、ミリスチン酸など)、より好ましくはカプリル酸、ぺラルゴン酸、カプリン酸及びラウリン酸である。脂肪酸の炭素数が8より小さい場合、得られたプロピレングリコール脂肪酸エステルは不快臭の発生や皮膚刺激性が強くなり、構成する脂肪酸の炭素数が14を超える場合、得られたプロピレングリコール脂肪酸エステルは静菌効果が弱く又は無くなるので好ましくない。 The fatty acid having 8 to 14 carbon atoms constituting the propylene glycol fatty acid ester may be either a saturated fatty acid or an unsaturated fatty acid, and preferably a linear saturated fatty acid having 8 to 14 carbon atoms (for example, caprylic acid, (Largonic acid, capric acid, lauric acid, myristic acid, etc.), more preferably caprylic acid, pelargonic acid, capric acid and lauric acid. When the number of carbon atoms of the fatty acid is less than 8, the resulting propylene glycol fatty acid ester has a strong unpleasant odor and skin irritation, and when the number of carbon atoms of the fatty acid exceeds 14, the resulting propylene glycol fatty acid ester is Since the bacteriostatic effect is weak or disappears, it is not preferable.
炭素数が8〜14の脂肪酸は、1種又は2種以上を用いることができ、脂肪酸全体中に好ましくは約50質量%以上、より好ましくは約70質量%以上、更により好ましくは約90質量%以上含有する脂肪酸又は脂肪酸混合物である。 The fatty acid having 8 to 14 carbon atoms can be used singly or in combination of two or more, preferably about 50% by mass or more, more preferably about 70% by mass or more, and still more preferably about 90% by mass in the whole fatty acid. % Fatty acid or fatty acid mixture.
上記プロピレングリコール脂肪酸エステルは、プロピレングリコールと上記脂肪酸のエステル化生成物から、未反応物及びジエステル体を可及的に除去し、モノエステル体の含有量を90質量%以上に精製したものであり、エステル化反応、除去及び精製等自体公知の方法で製造され得る。
上記プロピレングリコール脂肪酸エステルの製造方法の概略は下記の通りである。
例えば、攪拌機、加熱用のジャケット、邪魔板などを備えた通常の反応容器に、プロピレングリコールと炭素数8〜14の脂肪酸を約1:0.2〜1.5のモル比で仕込み、常法によりエステル化反応を行い、反応終了後、反応混合物中に残存する触媒を中和して反応液を得る。エステル化反応する際の加熱温度としては通常、約180〜260℃の範囲、好ましくは約190〜210℃の範囲である。また、反応圧力条件は減圧下又は常圧下で、反応時間は約0.5〜15時間、好ましくは約1〜10時間である。得られた反応液は、未反応の脂肪酸、未反応のプロピレングリコール、プロピレングリコールモノ脂肪酸エステル及びプロピレングリコールジ脂肪酸エステルなどを含む混合物である。この反応液を減圧下で蒸留して未反応のプロピレングリコールを留去し、続いて、例えば流下薄膜式分子蒸留装置又は遠心式分子蒸留装置などを用いて分子蒸留するか、又はカラムクロマトグラフィーもしくは液液抽出など自体公知の方法を用いて精製することにより、モノエステル体を90質量%以上含むプロピレングリコール脂肪酸エステルを得る。
The propylene glycol fatty acid ester is obtained by removing as much as possible unreacted substances and diester form from the esterification product of propylene glycol and the above fatty acid, and purifying the monoester form content to 90% by mass or more. , Esterification reaction, removal and purification can be produced by methods known per se.
The outline of the production method of the propylene glycol fatty acid ester is as follows.
For example, an ordinary reaction vessel equipped with a stirrer, a heating jacket, a baffle plate, etc. is charged with propylene glycol and a fatty acid having 8 to 14 carbon atoms in a molar ratio of about 1: 0.2 to 1.5. The esterification reaction is carried out, and after completion of the reaction, the catalyst remaining in the reaction mixture is neutralized to obtain a reaction solution. The heating temperature for the esterification reaction is usually in the range of about 180 to 260 ° C, preferably in the range of about 190 to 210 ° C. The reaction pressure is under reduced pressure or normal pressure, and the reaction time is about 0.5 to 15 hours, preferably about 1 to 10 hours. The obtained reaction liquid is a mixture containing unreacted fatty acid, unreacted propylene glycol, propylene glycol monofatty acid ester, propylene glycol difatty acid ester, and the like. This reaction solution is distilled under reduced pressure to distill off unreacted propylene glycol, followed by molecular distillation using, for example, a falling film molecular distillation device or a centrifugal molecular distillation device, or column chromatography or By purifying using a method known per se such as liquid-liquid extraction, a propylene glycol fatty acid ester containing 90% by mass or more of a monoester is obtained.
上記プロピレングリコール脂肪酸エステルとしては、商業的に製造及び販売されているものを用いることができ、例えば、リケマールPL−100(商品名;理研ビタミン社製 プロピレングリコールラウリン酸エステル モノエステル体含有量約95質量%)が挙げられる。 As said propylene glycol fatty acid ester, what is manufactured and sold commercially can be used, for example, Riquemar PL-100 (trade name; Propylene glycol laurate monoester content by Riken Vitamin Co., Ltd. about 95 Mass%).
かくして得られる本発明の腋臭原因菌に対する静菌剤は、コリネバクテリウム(Corynebacterium)属菌などの腋臭原因菌、特にCorynebacterium xerosisに対する静菌効果を発揮する。 The bacteriostatic agent against the odor-causing bacteria of the present invention thus obtained exerts a bacteriostatic effect against odor-causing bacteria such as Corynebacterium spp., Particularly Corynebacterium xerosis.
本発明の腋臭原因菌に対する静菌剤を含油する腋臭用皮膚外用剤も本発明の形態の1つである。腋臭用皮膚外用剤とは、腋臭の予防や治療を目的としたて皮膚に対して外用で用いられる製剤の総称であり、医薬又は化粧料として使用される。医薬として使用する場合には、軟膏剤、スティック状剤、水剤、エキス剤、ローション剤、乳剤、パップ剤などの形態とすることができる。例えば、軟膏剤とする場合には油性基剤をベースとするもの、水中油型又は油中水型の乳化系基剤をベースとするもののいずれでもよく、油性基材としては例えば植物油、動物油、合成油、脂肪酸及び天然又は合成のグリセライドなどがあげられる。また、当該医薬には、他の薬効成分、例えば鎮痛消炎剤、殺菌消毒剤、収斂剤、皮膚軟化剤、ホルモン剤、抗生物質などを適宜配合することができる。 The skin odor external preparation for oily odor containing the bacteriostatic agent for the odor-causing bacteria of the present invention is also one aspect of the present invention. The “smelling skin external preparation” is a general term for preparations used externally to the skin for the purpose of preventing and treating the stinking odor, and is used as a medicine or cosmetic. When used as a medicine, it can be in the form of an ointment, stick, liquid, extract, lotion, emulsion, cataplasm, and the like. For example, in the case of an ointment, any of those based on an oily base and those based on an oil-in-water or water-in-oil emulsified base may be used. Examples of oily bases include vegetable oils, animal oils, Examples include synthetic oils, fatty acids, and natural or synthetic glycerides. In addition, other medicinal ingredients such as analgesic / anti-inflammatory agents, bactericidal / disinfectants, astringents, emollients, hormones, antibiotics, and the like can be appropriately blended with the medicament.
化粧料として使用する場合には、種々の形態、例えば水中油型又は油中水型の乳化化粧料、クリーム、ジェル、化粧乳液、化粧水、油性化粧料、洗顔料、ファンデーション、パック、パップ剤、スプレー、ミスト、皮膚洗浄剤などとすることができる。当該化粧料にはさらに化粧料成分として一般に使用されている、油分、セラミド類、凝セラミド類、ステロール類、保湿剤、抗酸化剤、一重項酸素消去剤、粉末成分、色剤、紫外線吸収剤、美白剤、アルコール類、キレート剤、pH調製剤、防腐剤、増粘剤、色素類、香料、植物エキス、各種皮膚栄養剤などを任意に組み合わせて配合することができる。 When used as a cosmetic, various forms such as oil-in-water or water-in-oil emulsified cosmetics, creams, gels, cosmetic emulsions, lotions, oily cosmetics, facial cleansers, foundations, packs, poultices , Spray, mist, skin cleanser and the like. The cosmetics are further commonly used as cosmetic ingredients, such as oils, ceramides, coagulated ceramides, sterols, moisturizers, antioxidants, singlet oxygen scavengers, powder ingredients, colorants, UV absorbers. , Whitening agents, alcohols, chelating agents, pH adjusters, preservatives, thickeners, pigments, fragrances, plant extracts, various skin nutrients, and the like can be combined in any combination.
以下に本発明を実施例で説明するが、これは本発明を単に説明するだけのものであって、本発明を限定するものではない。 The present invention will now be described by way of examples, which are merely illustrative of the invention and do not limit the invention.
<腋臭原因菌に対する静菌剤の作製>
[試作品1の作製]
攪拌機、温度計、ガス吹き込み管及び水分離器を取り付けた3Lの四つ口フラスコにプロピレングリコール1080gとカプリン酸1320g及び酸化亜鉛0.24gを仕込み、窒素ガスを導入しつつ195℃に昇温し7時間反応を行い、酸価1.2の反応液2140gを得た。この反応液900gを減圧蒸留(100℃、250Pa)して未反応のプロピレングリコールを除去した後、さらに減圧蒸留(150℃、120Pa)し、プロピレングリコールカプリン酸エステル(実施例品)430gを得た。モノエステル体含有量は95質量%であった。
<Production of bacteriostatic agent against odor-causing bacteria>
[Production of prototype 1]
A 3 L four-necked flask equipped with a stirrer, thermometer, gas blowing tube and water separator was charged with 1080 g of propylene glycol, 1320 g of capric acid and 0.24 g of zinc oxide and heated to 195 ° C. while introducing nitrogen gas. Reaction was performed for 7 hours to obtain 2140 g of a reaction solution having an acid value of 1.2. After 900 g of this reaction liquid was distilled under reduced pressure (100 ° C., 250 Pa) to remove unreacted propylene glycol, it was further distilled under reduced pressure (150 ° C., 120 Pa) to obtain 430 g of propylene glycol capric acid ester (Example product). . The monoester content was 95% by mass.
[試作品2の作製]
攪拌機、温度計、ガス吹き込み管及び水分離器を取り付けた500mlの四つ口フラスコにプロピレングリコール106gとカプリン酸294g及び酸化亜鉛0.04gを仕込み、窒素ガスを導入しつつ195℃に昇温し6時間反応を行い、酸価1.7であるプロピレングリコールカプリン酸エステル(比較例品1)360gを得た。モノエステル体の含有量は50質量%であった。
[Production of prototype 2]
A 500 ml four-necked flask equipped with a stirrer, thermometer, gas blowing tube and water separator was charged with 106 g of propylene glycol, 294 g of capric acid and 0.04 g of zinc oxide, and heated to 195 ° C. while introducing nitrogen gas. Reaction was performed for 6 hours to obtain 360 g of propylene glycol capric acid ester (Comparative Example Product 1) having an acid value of 1.7. The monoester content was 50% by mass.
[モノエステル体含有量の測定法]
HPLCを用いてエステル組成分析を行い、定量は絶対検量線法により行った。即ち、データ処理装置によってクロマトグラム上に記録された被検試料のモノエステル体に相当するピーク面積を測定し、順相系カラムクロマトグラフィーにより精製したプロピレングリコールモノラウリン酸エステルを標準試料として作成した検量線から、被検試料のモノエステル体含有量を求めた。HPLC分析条件を以下に示した。
[Measurement method of monoester content]
The ester composition analysis was performed using HPLC, and the quantitative analysis was performed by the absolute calibration curve method. In other words, the peak area corresponding to the monoester form of the test sample recorded on the chromatogram by the data processor was measured, and the calibration was made using propylene glycol monolaurate purified by normal phase column chromatography as the standard sample. From the line, the monoester content of the test sample was determined. The HPLC analysis conditions are shown below.
[HPLC分析条件]
装置 島津高速液体クロマトグラフ
ポンプ(型式:LC−20AD;島津製作所社製)
カラムオーブン(型式:CTO−20A;島津製作所社製)
データ処理装置(型式:LCsolution;島津製作所社製)
カラム GPCカラム(型式:SHODEX KF−801;昭和電工社製) 2本連結
移動相 THF
流量 1.0mL/min
検出器 RI検出器(型式:RID−10A;島津製作所社製)
カラム温度 40℃
検液注入量 15μL(in THF)
[HPLC analysis conditions]
Equipment Shimadzu High Performance Liquid Chromatograph Pump (Model: LC-20AD; manufactured by Shimadzu Corporation)
Column oven (model: CTO-20A; manufactured by Shimadzu Corporation)
Data processing device (model: LCsolution; manufactured by Shimadzu Corporation)
Column GPC column (model: SHODEX KF-801; manufactured by Showa Denko KK) 2 linked mobile phase THF
Flow rate 1.0mL / min
Detector RI detector (model: RID-10A; manufactured by Shimadzu Corporation)
Column temperature 40 ° C
Test solution injection volume 15μL (in THF)
<静菌試験>
下記表1に示す腋臭原因菌に対する静菌剤を用いて、腋臭原因菌(Corynebacterium xerosis:C.xerosis)に対する静菌試験を行った。
<Bacteriostatic test>
Using a bacteriostatic agent against the odor-causing bacteria shown in Table 1 below, a bacteriostatic test was conducted against odor-causing bacteria (C. xerosis).
[接種用菌液の調製]
C.xerosisを、No702培地(ポリペプトン10g、酵母エキス2g、硫酸マグネシウム7水和物1g、蒸留水1Lを調整)に加えて菌数が1×105CFU/mLの接種用菌液を調整した。
[Preparation of bacterial solution for inoculation]
C. xerosis was added to No702 medium (10 g of polypeptone, 2 g of yeast extract, 1 g of magnesium sulfate heptahydrate, and 1 L of distilled water were prepared) to prepare a bacterial solution for inoculation having a bacterial count of 1 × 10 5 CFU / mL.
[最少阻止濃度(MIC)の測定]
48穴マイクロプレートの各ウェルに、培養液として、液体培地(No702培地)900μL、接種用菌液100μL及び上記の腋臭原因菌に対する静菌剤を培養液中の濃度が25ppm、50ppm、100ppm、200ppm、300ppm、400ppmとなるように希釈した溶液10μLを分注し、30℃で5日間培養して菌の生育の有無を確認した。この時、生育が認められなかった培養液を150μL採取し、No802培地(ポリペプトン10g、酵母エキス2g、硫酸マグネシウム7水和物1g、蒸留水1L、寒天15gを調整)に塗布し、さらに30℃で5日間培養した。この際、生育が認められなかった最少の濃度を最少阻止濃度(MIC)とした。結果を表2に示す。
[Measurement of minimum inhibitory concentration (MIC)]
In each well of a 48-well microplate, as a culture solution, 900 μL of liquid medium (No. 702 medium), 100 μL of the inoculum bacterial solution and the bacteriostatic agent for the above odor-causing bacteria are 25 ppm, 50 ppm, 100 ppm, 200 ppm in the culture solution. Then, 10 μL of a solution diluted to 300 ppm and 400 ppm was dispensed and cultured at 30 ° C. for 5 days to confirm the presence or absence of growth of the fungus. At this time, 150 μL of a culture solution in which growth was not observed was collected and applied to a No802 medium (adjusted with 10 g of polypeptone, 2 g of yeast extract, 1 g of magnesium sulfate heptahydrate, 1 L of distilled water, and 15 g of agar), and further 30 ° C. For 5 days. At this time, the minimum concentration at which no growth was observed was defined as the minimum inhibitory concentration (MIC). The results are shown in Table 2.
<皮膚刺激性確認テスト>
実施例品及び参考例品1についての皮膚刺激性を、パッチテスト(閉塞パッチテスト法)により確認した。この手法は、化粧料等の皮膚刺激性を確認する目的で一般的に用いられている手法である。
<Skin irritation confirmation test>
The skin irritation of the example product and the reference product 1 was confirmed by a patch test (occlusion patch test method). This technique is generally used for the purpose of confirming skin irritation such as cosmetics.
[希釈液の作製]
蒸留水(89.5g)、エタノール(10.0g)、実施例品(0.5g)を混合して実施例品を0.5質量%含む希釈液1を作製した。また、実施例品に替えて参考例品1を用いて参考例品1を0.5質量%含む希釈液2を作製した。
[Production of diluted solution]
Distilled water (89.5 g), ethanol (10.0 g), and the example product (0.5 g) were mixed to prepare a diluent 1 containing 0.5% by mass of the example product. In addition, a dilute solution 2 containing 0.5% by mass of the reference example product 1 was produced using the reference example product 1 instead of the example product.
[皮膚刺激性確認テストの実施]
得られた希釈液1及び2をそれぞれ直径5mm程の円形ろ紙にしみ込ませ、これを上腕部にろ紙と同径のアルミニウム製円盤(フィンチャンバー)を用いて貼付し48時間固定した。48時間後に貼付したろ紙を剥がし(パッチ除去)、その後1時間及び24時間経過後の皮膚の刺激反応状態を判定した。判定は、表3の判定基準で皮膚の反応を評価した。そして皮膚に反応があらわれた人数に各判定の係数を乗じたものの和を評点とし、評点を被験者の人数(8名)で割り100倍した値を刺激指数とした。刺激指数が、概ね10以下は安全品、10〜30は許容品、30以上は要改良品と評価した。皮膚反応状態の判定、評点、刺激指数、評価を表4に示す。
[Implementation test for skin irritation]
The obtained dilutions 1 and 2 were each soaked in a circular filter paper having a diameter of about 5 mm, and this was pasted on the upper arm using an aluminum disk (fin chamber) having the same diameter as the filter paper and fixed for 48 hours. The filter paper affixed after 48 hours was peeled off (patch removal), and then the skin irritation state after 1 hour and 24 hours was determined. In the determination, the skin reaction was evaluated according to the determination criteria shown in Table 3. Then, the sum of the number of people who had a reaction on the skin multiplied by the coefficient of each judgment was used as a score, and the value obtained by dividing the score by the number of subjects (8 people) and multiplying by 100 was used as the stimulation index. The stimulation index was evaluated as a safety product, 10 to 30 as an acceptable product, 10 to 30 as an acceptable product, and 30 or more as an improved product. Table 4 shows the skin reaction state determination, score, stimulation index, and evaluation.
<腋臭用皮膚外用剤の作製>
[腋臭用皮膚外用剤1]
下記表5の配合により、各成分を均一に混合して実施例品を含有する腋臭用皮膚外用品1(スティックデオドラント)を作製した。
<Preparation of skin external preparation for bad smell>
[Skin external preparation for bad smell 1]
According to the formulation shown in Table 5 below, each component was uniformly mixed to prepare a skin odor product 1 (stick deodorant) containing example products.
[腋臭用皮膚外用剤2]
下記表6の配合により、各成分を均一に混合して実施例品を含有する腋臭用皮膚外用剤2(腋臭用液体防臭剤)を作製した。
[Skin external preparation for smelly odor 2]
According to the formulation shown in Table 6 below, each component was uniformly mixed to prepare a skin odor preparation for odor 2 (liquid odor deodorant for odor) containing the examples.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013190027A JP6242636B2 (en) | 2013-09-13 | 2013-09-13 | Bacteriostatic agent against odor-causing bacteria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013190027A JP6242636B2 (en) | 2013-09-13 | 2013-09-13 | Bacteriostatic agent against odor-causing bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015054850A JP2015054850A (en) | 2015-03-23 |
| JP6242636B2 true JP6242636B2 (en) | 2017-12-06 |
Family
ID=52819483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013190027A Active JP6242636B2 (en) | 2013-09-13 | 2013-09-13 | Bacteriostatic agent against odor-causing bacteria |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6242636B2 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0899852A (en) * | 1994-08-04 | 1996-04-16 | Taiyo Kagaku Co Ltd | Armpit prevention |
| DE102004046603A1 (en) * | 2004-09-25 | 2006-03-30 | Goldschmidt Gmbh | Agent for treating microorganisms e.g. mycobacteria and viruses, and for preparing food preservatives and cosmetic formulation, comprises mixture of fatty acid ester of polyol and salts of short chain monocarboxylic acid |
-
2013
- 2013-09-13 JP JP2013190027A patent/JP6242636B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015054850A (en) | 2015-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2929645T3 (en) | Cosmetic, dermatological or pharmaceutical composition comprising at least one vanillin derivative as a preservative | |
| US9776951B2 (en) | Polyglycerol esters with a particular oligomer distribution of the polyglycerol | |
| EP0775478B1 (en) | Combinations of active ingredients based on partial glycerides and dialkylsubstituted acetic acids efficient against bacteria, mycoses and viruses | |
| Nunes et al. | Potential therapeutic of olive oil industry by-products in skin health: A review | |
| WO2018084112A1 (en) | Acne strain-selective antibacterial agent | |
| EP0821948A2 (en) | Combination of active ingredients based on partial glycerides and dialkylsubstituted acetic acids efficient against bacteria, mycoses and viruses | |
| JPH04139125A (en) | Dermal external preparation for acne vulgaris | |
| KR20210019202A (en) | Cosmetic composition for regulating microbe in skin comprising extract of zanthoxylum piperitum fruit or fractions from thereof | |
| JP2021042241A (en) | Composition for external use | |
| WO2012108494A1 (en) | Deodorant containing polyvalent alcohol | |
| JP6242636B2 (en) | Bacteriostatic agent against odor-causing bacteria | |
| WO2003055559A1 (en) | Dialkyl-substituted acetic acid and glyceric acid based active substance combinations against bacteria, mycota and viruses | |
| US20060093689A1 (en) | Skin cosmetics | |
| JP2001302483A (en) | Deodorant | |
| JP6234752B2 (en) | Bacteriostatic agents against acne-causing bacteria | |
| JP6150271B2 (en) | Bacteriostatic agent for oral aerobic bacteria | |
| JP2012219046A (en) | Deodorant composition for external application to skin | |
| KR101363028B1 (en) | A cosmetic composition for the prevention, improvement or treatment of acne vulgaris comprising the mixture of extract of Melissa officinalis, Citrus bergamia, leaves of Mentha arvensis, Eclipta prostrata and Hovenia dulcis Thunb | |
| JP4220769B2 (en) | Anti-acne bacteria composition | |
| CA3181110A1 (en) | An antimicrobial composition for tackling malodour | |
| DE10147545A1 (en) | Active ingredient combinations based on polyhydric alcohols and dialkyl-substituted acetic acids are effective against bacteria Mycota and viruses | |
| JPH08208467A (en) | Composition of active compound used for heavy infection containing wool wax acid mixture and other fatty acid | |
| JP2010275201A (en) | Solubilized cosmetic composition | |
| Varvaresou et al. | Efficacy tests of Alternative Preservatives in combination with Phenoxyethanol for Development of Safe Cosmetic Products for Children. | |
| DE10034137A1 (en) | Active ingredient combinations of 3-iodo-2-propynyl butyl carbamate and one or more 4-hydroxybenzoic acid esters and preparations containing such active ingredient combinations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160901 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170626 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170704 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171107 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171108 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6242636 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313532 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |